Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Radiation Oncology
•
Thoracic Malignancies
What dose contraints do use for the pulmonary artery and vein when treating with a lung lesion with SBRT?
Related Questions
What systemic therapy would you offer to a patient with metastatic EGFR exon 19 deleted NSCLC to the brain with isolated CNS progression while on osimertinib 80 mg and progressed through WBRT?
Did NRG LU004 demonstrate safety with hypofractionated lung radiation and concurrent ICI?
In what situations would immunotherapy alone be appropriate for non-metastatic NSCLC?
How would you approach an in-field recurrence after lung SBRT for a T1 NSCLC in a patient with poor underlying lung function?
How often, if ever, do patients with initially negative targetable mutation workup become positive later in recurrent lung cancer?
Would you offer SBRT for a lung lesion adjacent to the heart in a patient receiving bevacizumab?
How would you approach SBRT in a pacemaker-dependent elderly patient with Stage I NSCLC whose SBRT plan Dmax exceeds the pacemaker tolerance?
How would you treat a patient with newly diagnosed ALK+ Stage IIIB non-small cell lung cancer (NSCLC)?
What are your top takeaways in Thoracic Cancers from ASTRO 2024?
What would be your approach in a patient who presented with a solitary brain metastasis that resolved after chemo without local therapy?
